Skip to main content

Advertisement

Table 6 Risk for tertiary individual CV endpoints with linagliptin versus total comparators based on Cox hazard model

From: Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme

  Cox HR (95% CI)
CV death 0.74 (0.10-5.33)
Non-fatal MI 0.52 (0.17-1.54)
Non-fatal stroke 0.11 (0.02-0.51)
TIA 0.17 (0.02-1.53)
UAP with hospitalization 0.24 (0.02-2.34)
UAP without hospitalization 0.73 (0.04-12.02)
SAP 1.06 (0.44-2.58)
Total mortality 1.02 (0.23-4.63)
  1. CI, confidence interval; CV; cardiovascular; HR, hazard ratio; MI, myocardial infarction; SAP, stable angina pectoris; TIA, transient ischaemic attack; UAP, unstable angina pectoris.